Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aradigm Corporation (NASDAQ:ARDM), General Motors Company (NYSE:GM), AT&T Inc. (NYSE:T), Denbury Resources Inc. (NYSE:DNR), Novavax, Inc. (NASDAQ:NVAX), and Immunomedics, Inc. (NASDAQ:IMMU), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ARDM DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARDM GM DOWNLOAD: http://Fundamental-Markets.com/register/?so=GM T DOWNLOAD: http://Fundamental-Markets.com/register/?so=T DNR DOWNLOAD: http://Fundamental-Markets.com/register/?so=DNR NVAX DOWNLOAD: http://Fundamental-Markets.com/register/?so=NVAX IMMU DOWNLOAD: http://Fundamental-Markets.com/register/?so=IMMU

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Aradigm Corporation (NASDAQ:ARDM), General Motors Company (NYSE:GM), AT&T Inc. (NYSE:T), Denbury Resources Inc. (NYSE:DNR), Novavax, Inc. (NASDAQ:NVAX), and Immunomedics, Inc. (NASDAQ:IMMU) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. All information in this release was accessed November 24th, 2017. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All amounts in millions (except per share amounts).

-----------------------------------------

Aradigm Corporation (ARDM) REPORT OVERVIEW

Aradigm's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Aradigm reported revenue of $2.73 vs $0.05 (up 5,356%) and diluted earnings per share -$0.26 vs -$0.55. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Aradigm reported revenue of $0.20 vs $23.43 (down 99.17%) and diluted earnings per share -$2.23 vs -$1.17. Aradigm is expected to report earnings on March 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.54. The estimated EPS forecast for the next fiscal year is -$0.40 and is expected to report on March 27th, 2018.

To read the full Aradigm Corporation (ARDM) report, download it here: http://Fundamental-Markets.com/register/?so=ARDM

-----------------------------------------

General Motors Company (GM) REPORT OVERVIEW

General Motors' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, General Motors reported revenue of $33,623.00 vs $38,889.00 (down 13.54%) and diluted earnings per share -$2.03 vs $1.76. For the twelve months ended December 31st, 2016 vs December 31st, 2015, General Motors reported revenue of $166,380.00 vs $152,356.00 (up 9.20%) and diluted earnings per share $6.00 vs $5.91 (up 1.52%). General Motors is expected to report earnings on February 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $1.28. The estimated EPS forecast for the next fiscal year is $5.84 and is expected to report on February 6th, 2018.

To read the full General Motors Company (GM) report, download it here: http://Fundamental-Markets.com/register/?so=GM

-----------------------------------------

AT&T Inc. (T) REPORT OVERVIEW

AT&T's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, AT&T reported revenue of $39,668.00 vs $40,890.00 (down 2.99%) and diluted earnings per share $0.49 vs $0.54 (down 9.26%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, AT&T reported revenue of $163,786.00 vs $146,801.00 (up 11.57%) and diluted earnings per share $2.10 vs $2.37 (down 11.39%). AT&T is expected to report earnings on January 24th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.66. The estimated EPS forecast for the next fiscal year is $2.98 and is expected to report on January 24th, 2018.

To read the full AT&T Inc. (T) report, download it here: http://Fundamental-Markets.com/register/?so=T

-----------------------------------------

Denbury Resources Inc. (DNR) REPORT OVERVIEW

Denbury Resources' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Denbury Resources reported revenue of $266.56 vs $253.99 (up 4.95%) and diluted earnings per share $0.00 vs -$0.06. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Denbury Resources reported revenue of $975.60 vs $1,257.56 (down 22.42%) and diluted earnings per share -$2.61 vs -$12.57. Denbury Resources is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is $0.12 and is expected to report on February 22nd, 2018.

To read the full Denbury Resources Inc. (DNR) report, download it here: http://Fundamental-Markets.com/register/?so=DNR

-----------------------------------------

Novavax, Inc. (NVAX) REPORT OVERVIEW

Novavax's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Novavax reported revenue of $8.35 vs $3.23 (up 158.50%) and diluted earnings per share -$0.15 vs -$0.24. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Novavax reported revenue of $15.35 vs $36.25 (down 57.65%) and diluted earnings per share -$1.03 vs -$0.60. Novavax is expected to report earnings on February 26th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.21. The estimated EPS forecast for the next fiscal year is -$0.54 and is expected to report on February 26th, 2018.

To read the full Novavax, Inc. (NVAX) report, download it here: http://Fundamental-Markets.com/register/?so=NVAX

-----------------------------------------

Immunomedics, Inc. (IMMU) REPORT OVERVIEW

Immunomedics' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Immunomedics reported revenue of $0.69 vs $0.74 (down 6.92%) and diluted earnings per share -$0.97 vs -$0.17. For the twelve months ended June 30th, 2017 vs June 30th, 2016, Immunomedics reported revenue of $3.09 vs $3.23 (down 4.39%) and diluted earnings per share -$1.47 vs -$0.62. Immunomedics is expected to report earnings on February 8th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is -$0.01 and is expected to report on August 15th, 2018.

To read the full Immunomedics, Inc. (IMMU) report, download it here: http://Fundamental-Markets.com/register/?so=IMMU

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@fundamental-markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: andrew.duffie@fundamental-markets.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024